Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03159702
Recruitment Status : Recruiting
First Posted : May 19, 2017
Last Update Posted : March 25, 2020
Sponsor:
Information provided by (Responsible Party):
Mehdi Hamadani, Medical College of Wisconsin

Brief Summary:
This is an open-label, single-arm, phase II study to determine the safety of propylene glycol-free melphalan HCl (EVOMELA®), in combination with fludarabine and total-body irradiation-based reduced-intensity conditioning for haploidentical transplantation. In addition, the study evaluates the one-year progression-free survival of patients undergoing this treatment.

Condition or disease Intervention/treatment Phase
Hematological Malignancy Leukemia Multiple Myeloma Lymphoma Drug: Evomela Drug: Fludarabine Radiation: Total Body Irradiation Phase 2

Detailed Description:

OVERVIEW:

Elderly and infirm patients with hematological malignancies often cannot undergo allogeneic hematopoietic cell transplantation (HCT) because of high-toxicity rates and nonrelapse mortality (NRM) associated with higher-intensity conditioning allografts.

Reduced-intensity conditioning (RIC) transplantation has emerged as an attractive alternative for these populations.

FLUDARABINE/MELPHALAN. In RIC, fludarabine is often used as the lymphocyte-depleting component to facilitate donor-cell engraftment. This drug can be given once daily because of its plasma half-life. M.D. Anderson pioneered the use of fludarabine melphalan (FLU/MEL) conditioning, which has since gained wide usage. (1) Melphalan is convenient, has broad antitumor activity in hematologic malignancies and has immunosuppressive effects. The Flu/Mel conditioning regimen can provide long-term disease control, especially in the subset of patients with chemo sensitive disease. (1) TOTAL-BODY IRRADIATION. In a recent study, total-body irradiation (200 cGy) was used with flu/mel for advanced lymphoma treated with HCT. With a median follow-up time close to two years, the survival of these mostly advanced, relapsed/refractory patients was very encouraging with overall survival of 54% and progression-free survival of 54% for the entire group. (2) Treatment-related mortality was low at day 100 (9.1%) and two years (19%) after transplantation, with stable engraftment achieved in the great majority of patients.

PROPYLENE GLYCOL-FREE MELPHALAN HCL (EVOMELA®). In theory, intensifying the dose of melphalan in flu/mel conditioning could provide better disease control post HCT, allowing more time for curative graft-versus-leukemia effects to emerge. The use of the commercial formulation of melphalan (Alkeran®) proved somewhat problematic, however, because it must be reconstituted with propylene glycol, a substance that has been associated with toxic side effects. The substitution of Captisol® in propylene glycol-free melphalan HCl (EVOMELA®) for Injection (Spectrum Pharmaceuticals, Inc.) for the excipients found in Alkeran®, directly overcomes the formulation limitations noted with Alkeran®.

STUDY RATIONALE. The preliminary data suggest that the substitution of Captisol® in EVOMELA® for the excipients found in Alkeran® directly overcomes the formulation limitations and provides a potentially safer melphalan formulation for administration at higher doses used in HCT conditioning regimens.

Based on these observations, we now propose a phase II study of a RIC regimen consisting of EVOMELA® in combination with fludarabine and total-body irradiation for patients undergoing haplo-HCT. The study will investigate the safety and tolerability of this conditioning approach. While the FDA indication for EVOMELA® is for myeloablative conditioning prior to autologous HCT in patients with multiple myeloma, we anticipate our study will provide critical preliminary data to explore this formulation in allogeneic HCT conditioning.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 43 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Actual Study Start Date : December 8, 2017
Estimated Primary Completion Date : July 1, 2021
Estimated Study Completion Date : July 1, 2023


Arm Intervention/treatment
Experimental: MEL/FLU and Total-Body Irradiation (TBI)

For patients who are < 60 years.

  • Melphalan: 140 mg/m2/day IV on Day: -6
  • Fludarabine: 40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance (CrCl) may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].)
  • TBI: 200 cGy Day: -1.

For patients who are ≥ 60 years.

  • Melphalan: 100 mg/m2/day IV on Day: -6
  • Fludarabine: 40 mg/ m2/day IV Days: -5, -4, -3, -2
  • TBI: 200 cGy; Days: -2, -1 (total of 400cGy)

For patients who are ≥60 years and/or Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score of >3 (at the discretion of treating physician will have an option to receive):

  • Melphalan: 70 mg/m2/day IV on Day -6.
  • Fludarabine: 40 mg/m2/day IV Days -5, -4, -3, -2.
  • TBI: 200 cGy; Days -1.
Drug: Evomela
140 mg/m2/day IV on Day -6 for patients who are < 60 years of age. 100 mg/m2/day IV on Day -6 for patients who are ≥ 60 years 70 mg/m2/day IV on Day -6 For patients who are ≥60 years and/or HCT-CI score of >3
Other Name: Melphalan

Drug: Fludarabine

40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].) for patients who are < 60 years of age.

40 mg/ m2/day IV Days: -5, -4, -3, -2 for patients who are ≥ 60 years. 40 mg/m2/day IV Days -5, -4, -3, -2. For patients who are ≥60 years and/or HCT-CI score of >3

Other Name: Fludara

Radiation: Total Body Irradiation
200 cGy Day: -1 for patients who are < 60 years of age. 200 cGy; Days: -2, -1 (total of 400cGy) for patients who are ≥ 60 years. 200 cGy; Days -1. For patients who are ≥60 years and/or HCT-CI score of >3.




Primary Outcome Measures :
  1. The number of patients with one-year progression-free survival (PFS) of participants with hematological malignancies undergoing treatment. [ Time Frame: 1 year ]
    Progression-free survival (PFS) is defined as the length of time during and after the treatment that a participant lives with the disease but it does not get worse.

  2. The safety of this trial will be evaluated with the nonrelapse mortality rate. [ Time Frame: 1 Year ]
    This is the number of participants expiring unrelated to relapse of disease.


Secondary Outcome Measures :
  1. Overall survival following reduced-intensity conditioning haploidentical transplantation. [ Time Frame: 1 Year and 2 Year ]
    The number of participants still alive following reduced-intensity conditioning haploidentical transplantation.

  2. Relapse rate following reduced-intensity conditioning haploidentical transplantation at Day 100 and 1 Year. [ Time Frame: Day 100 and 1 Year ]
    The number of participants who relapse following reduced-intensity conditioning haploidentical transplantation at Day 100 and 1 Year.

  3. The time from reduced-intensity conditioning haploidentical transplantation to neutrophil recovery. [ Time Frame: Day 30 ]
    The average of the number of days that it takes for neutrophil recovery from reduced-intensity conditioning haploidentical transplantation.

  4. The time from reduced-intensity conditioning haploidentical transplantation to platelet recovery. [ Time Frame: Day 30 ]
    The average of the number of days that it takes for platelet recovery from reduced-intensity conditioning haploidentical transplantation.

  5. Acute graft-versus-host disease (GVHD) at day 100 and 180. [ Time Frame: Days 100 and 180. ]
    The number of participants with graft-versus-host disease.

  6. Rates of chronic GVHD at one-year post transplantation. [ Time Frame: 1 Year ]
    Incidence of chronic GVHD at one-year post transplantation.

  7. Rates of primary graft failure. [ Time Frame: Day 35 ]
    Incidence of primary graft failure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with a diagnosis of hematological malignancy undergoing a related donor haploidentical HCT.*
  • Patients aged ≥18 are eligible.
  • Bilirubin ≤ 2 x the upper limit of normal (ULN). For patients with Gilbert's syndrome or suspected mild veno-occlusive disease, bilirubin ≤ 3 x ULN is permitted.
  • Adequate renal function as defined by a serum creatinine clearance of > 30 mL/min calculated by Cockcroft-Gault equation.
  • Left ventricular ejection fraction ≥40%. No uncontrolled arrhythmias or New York Heart Association class III-IV heart failure.
  • Forced expiratory volume (FEV1) or diffusion capacity for carbon monoxide (DLCO) corrected for hemoglobin ≥ 50% of predicted.
  • Karnofsky performance status > 60.
  • Graft source of peripheral blood (the infused cluster of differentiation 34 (CD34)+ cell dose will be capped at 5 x 10^6 CD34+ cells/kg recipients actual body weight) or bone marrow (the ideal infused total nucleated cell dose (TNC) will be targeted at 4 x 108/kg recipient actual body weight).
  • A negative pregnancy test will be required for all women of child bearing potential. Females of child bearing potential should agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug and must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.). Breast-feeding is not permitted.
  • Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, or must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
  • No evidence of uncontrolled bacterial, viral or fungal infections at the time of enrollment.
  • Transplant recipient able to give informed consent. * Patients must be human leukocyte antigen (HLA) typed at high resolution using DNA based typing at the following HLA loci: HLA-A, -B, -C and DRB1 and have available: A related haploidentical bone marrow donor with two, three or four HLA-mismatches. A unidirectional mismatch in either the graft-versus-host or host-versus-graft direction is considered a mismatch. The donor and recipient must be HLA identical for at least one antigen (using high-resolution DNA-based typing) at the following genetic loci: HLA-A, HLA-B, HLA-C, and HLA-DRB1. Fulfillment of this criterion shall be considered sufficient evidence that the donor and recipient share one HLA haplotype, and typing of additional family members is not required.

Exclusion Criteria:

  • Patient must not have a healthy, eligible and readily available HLA-identical sibling donor or a volunteer adult unrelated donor (matched at allele-level at HLA-A, -B, -C and -DRB1).
  • No serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.\
  • Presence of active disease in acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): patients with active disease defined as >5% blasts in bone marrow and/or circulating leukemic blasts in peripheral blood, patients with known active central nervous disease involvement with leukemia/lymphoma or lymphoma patients with progressive disease on clinical and/or radiographic assessment are not eligible for this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03159702


Contacts
Layout table for location contacts
Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office 414-805-8900 cccto@mcw.edu

Locations
Layout table for location information
United States, Wisconsin
Froedtert Hospital & the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Principal Investigator: Mehdi H Hamadani, MD         
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Layout table for investigator information
Principal Investigator: Mehdi Hamadani Medical College of Wisconsin
Publications:
Layout table for additonal information
Responsible Party: Mehdi Hamadani, Associate Professor, Department of Medicine, Division of Hematology/Oncology, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT03159702    
Other Study ID Numbers: PRO29507
First Posted: May 19, 2017    Key Record Dates
Last Update Posted: March 25, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Mehdi Hamadani, Medical College of Wisconsin:
hematological malignancy
EVOMELA
Melphalan HCl
Total Body Irradiation
Reduced Intensity Conditioning
Haploidentical Transplantation
Fludarabine
Hematologic Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms
Hematologic Neoplasms
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Neoplasms by Site
Fludarabine
Melphalan
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists